Growth Hormone Stimulation Test: How to Interpret Your Result

What the Growth Hormone Stimulation Test Actually Measures

The test does not measure your baseline GH level. It measures how high your pituitary can push GH when deliberately provoked. Resting GH pulses are episodic and often undetectable, so a single random draw is nearly useless for diagnosing deficiency. The stimulation test bypasses that problem by using a pharmacological agent to drive a maximal response, then capturing the peak value across serial blood draws [1].

Why Random GH Draws Fail

Serum GH follows ultradian pulses, with most secretion occurring during slow-wave sleep. Between pulses, GH is frequently undetectable even in healthy adults. A random daytime GH of 0.1 ng/mL could be completely normal if it falls between pulses, or it could reflect true deficiency. Only a stimulated peak clarifies which situation applies [2].

The Role of IGF-1 as a Companion Marker

Insulin-like growth factor 1 (IGF-1) integrates GH secretion over 24 hours and has a much longer serum half-life. A low IGF-1 (below the age-matched and sex-matched reference range) strengthens the case for GH deficiency, but IGF-1 can be suppressed by malnutrition, liver disease, or hypothyroidism independent of GH status. The Endocrine Society's 2011 guideline states: "A subnormal serum IGF-1 concentration in a patient with pituitary disease is highly suggestive of GHD, but a normal value does not exclude it" [3]. That is why the stimulation test remains the diagnostic standard.

Common Stimulation Agents and Their Reference Cutoffs

Different provocative agents produce different peak GH thresholds. Using the wrong cutoff for the wrong test is one of the most common interpretation errors seen in practice.

Insulin Tolerance Test (ITT)

The insulin tolerance test is still considered the gold-standard provocative test by the Endocrine Society, provided adequate hypoglycemia (blood glucose below 40 mg/dL) is confirmed [3]. Intravenous regular insulin (0.1-0.15 units/kg) is given, and GH is sampled at 0, 30, 45, 60, and 90 minutes. A peak GH at or above 5.1 ng/mL on a chemiluminescence immunoassay rules out deficiency. Values below 3 ng/mL on the same assay class confirm severe deficiency. Results between 3 and 5.1 ng/mL occupy a gray zone requiring clinical judgment.

The ITT is contraindicated in patients with seizure disorders, ischemic heart disease, or a history of unexplained loss of consciousness. In those patients, GHRH-arginine is the preferred alternative [3].

GHRH-Arginine Test

GHRH (1 mcg/kg IV) combined with arginine infusion (0.5 g/kg IV over 30 minutes, maximum 30 g) is the most widely used alternative in adults. Cutoffs depend on body mass index because adiposity blunts the GH response independently of pituitary reserve [4]:

• BMI <25 kg/m2: peak GH below 11 ng/mL confirms deficiency
• BMI 25-30 kg/m2: peak GH below 8 ng/mL confirms deficiency
• BMI >30 kg/m2: peak GH below 4 ng/mL confirms deficiency

These BMI-stratified cutoffs were established by Corneli et al. (2005) in a cohort of 318 adults and subsequently endorsed by the Endocrine Society and the Growth Hormone Research Society [4].

Glucagon Stimulation Test

Glucagon (1 mg IM, or 1.5 mg for patients over 90 kg) has emerged as a practical alternative when neither ITT nor GHRH is available. GH samples are drawn at 0, 60, 90, 120, 150, and 180 minutes. A peak GH below 3 ng/mL suggests deficiency, though the cutoff has been revised downward from the older 3 ng/mL threshold to approximately 1 ng/mL in some centers using newer immunoassays [5]. The test takes longer (up to 3 hours) and carries a risk of delayed hypoglycemia, so patients are typically kept under observation and fed before discharge.

Macimorelin Stimulation Test

Macimorelin (Macrilen) is an oral GH secretagogue approved by the FDA in 2017 specifically for adult GH deficiency diagnosis [6]. A single 0.5 mg/kg oral dose is given after an 8-hour fast, and GH is sampled at 30, 45, 60, and 90 minutes. The FDA-approved cutoff is a peak GH below 2.8 ng/mL for deficiency. In the key trial (N=157), macimorelin showed 82% sensitivity and 92% specificity against the ITT [6]. Its oral route and minimal adverse-effect profile make it appealing in outpatient telehealth settings.

How to Read Your Actual Lab Report

Your report will list individual time-point GH values and, in most cases, flag a peak. The number that matters is the highest single value across all draws, not the average.

Units and Assay Calibration

GH can be reported in ng/mL or mIU/L. The conversion factor is approximately 1 ng/mL = 3 mIU/L using the IS 98/574 international standard, though older assays used IS 80/505 and produced values roughly 2-fold higher. If your cutoff reference was established with one standard and your lab uses another, apparent discordance may be a calibration artifact rather than a true clinical finding. Ask your ordering provider which assay your lab uses [7].

What "Peak GH" Means on Your Report

If the report simply shows a column of values, identify the single highest number. A peak GH of 8.4 ng/mL on a GHRH-arginine test in a patient with a BMI of 22 kg/m2 is above the 11 ng/mL cutoff, confirming a normal pituitary GH response. The same value of 8.4 ng/mL in a patient with a BMI of 32 kg/m2 is above the 4 ng/mL cutoff for that BMI stratum, still normal. Context always matters.

The Gray Zone

A peak GH between the deficient and clearly normal thresholds requires a second stimulation test using a different agent, or a composite clinical assessment incorporating IGF-1 z-score, pituitary MRI findings, and the number of additional pituitary hormone deficiencies present. The Endocrine Society guideline notes that patients with three or more pituitary hormone deficiencies and a low IGF-1 have greater than 97% probability of GH deficiency, and a stimulation test may not add diagnostic certainty in that specific scenario [3].

What a Low Result Means

A peak GH below the assay-specific and test-specific cutoff indicates inadequate pituitary GH reserve, consistent with adult GH deficiency (AGHD). This does not automatically mean you need GH replacement therapy. The decision to treat depends on symptom burden, IGF-1 levels, cardiovascular risk factors, bone density, and quality-of-life measures [3].

Causes of a Low GH Response

The most common structural cause is a pituitary adenoma or the treatment effects from surgery or radiation delivered to the sellar region. Traumatic brain injury accounts for a growing proportion of AGHD diagnoses; a 2016 meta-analysis covering 1,014 patients with traumatic brain injury found GH deficiency in approximately 15-20% of cases within 12 months of injury [8]. Idiopathic isolated GH deficiency is less common in adults than in children.

Obesity as a Confounder

Excess adiposity blunts GH release through increased somatostatin tone and elevated free fatty acids. A patient with a BMI of 35 kg/m2 may show a low peak GH that reflects attenuated secretion from obesity rather than true pituitary disease. Applying the BMI-adjusted GHRH-arginine cutoffs described above substantially reduces false-positive diagnoses in obese patients [4].

Next Steps After a Low Result

A confirmed low result should prompt:

1. Full pituitary hormone panel: TSH/free T4, morning cortisol or cosyntropin stimulation test, LH/FSH with testosterone (men) or estradiol (women), prolactin.
2. Pituitary MRI with gadolinium contrast to identify structural lesions.
3. Repeat IGF-1 after correcting any hypothyroidism or severe nutritional deficit, which can suppress IGF-1 independently.
4. Referral to a board-certified endocrinologist for consideration of recombinant human GH (rhGH) therapy if diagnosis is confirmed.

What a High Result Means

A peak GH well above the normal threshold does not indicate disease. It simply confirms that your pituitary is capable of strong secretion. Very high stimulated GH values are not clinically actionable on their own.

When High GH Becomes Relevant

The stimulation test is not the primary tool for diagnosing GH excess (acromegaly or gigantism). Acromegaly is diagnosed by demonstrating failure to suppress GH below 1 ng/mL after a 75-gram oral glucose load, combined with elevated IGF-1 [9]. A high stimulated GH on a stim test in a patient without symptoms of acromegaly (enlarged hands or feet, coarsened facial features, jaw prognathism, hyperhidrosis) has no pathological significance.

Elevated GH on Stim Test in Context of Acromegaly Evaluation

In patients already suspected of acromegaly, a markedly elevated GH across all time points of a stimulation test can be consistent with autonomous GH secretion, but the oral glucose suppression test (OGTT-GH) is the correct confirmatory study. The Endocrine Society's acromegaly guideline specifies the OGTT-GH, not a stimulation test, as the biochemical diagnostic standard [9].

Factors That Alter GH Stimulation Test Results

Several physiological and pharmacological variables can shift your peak GH up or down, independent of actual pituitary function.

Factors That Lower Peak GH (Risk of False Positive Deficiency)

• Obesity (BMI >30 kg/m2): Somatostatin tone is elevated, reducing net pituitary GH release.
• Oral estrogen therapy: Oral estrogens increase somatostatin and reduce GH sensitivity; transdermal estradiol has a smaller effect. The Endocrine Society recommends switching women on oral estrogen to a transdermal formulation at least 4-6 weeks before testing [3].
• Hypothyroidism: Free T4 below reference range suppresses GH secretion and IGF-1 production. Thyroid status should be optimized before performing a stimulation test.
• Glucocorticoid excess: Both exogenous and endogenous hypercortisolism blunt GH secretion.
• Hyperglycemia at the time of testing: Elevated blood glucose suppresses GH release.

Factors That Raise Peak GH (Risk of False Negative in True Deficiency)

• Puberty or recent sex steroid priming: Adolescents and young adults have substantially higher GH secretion. Some pediatric protocols prime with estradiol or testosterone before testing to reduce false-positive diagnoses.
• Recent vigorous exercise: GH rises acutely with high-intensity exercise; testing within 24 hours of intense training may artifactually raise results.
• Low somatostatin tone states: Certain physiological states temporarily reduce somatostatin inhibition.

Raising a Low GH Response: Clinical Interventions

If your result is low and GH deficiency is confirmed, recombinant human GH (somatropin) is the direct replacement therapy. The starting dose for adults is typically 0.1-0.2 mg/day subcutaneously, titrated upward based on IGF-1 response and tolerability, with a target IGF-1 in the upper half of the age-matched reference range [3].

Lifestyle Modifications That Support GH Secretion

For patients in a diagnostic gray zone or those not yet eligible for rhGH, certain modifiable factors can be addressed:

• Weight reduction: A 10% reduction in body weight in obese adults has been shown to meaningfully increase stimulated GH peaks in some studies, by reducing somatostatin tone [10].
• Sleep optimization: The majority of GH secretion occurs during slow-wave (stage 3) sleep. Sleep disorders, particularly obstructive sleep apnea, suppress nocturnal GH pulses. Treatment with CPAP in patients with confirmed OSA may partially restore GH pulsatility.
• Minimizing oral estrogen: As noted, switching to transdermal estradiol reduces the oral-estrogen-specific suppression of GH.

What to Avoid Before Retesting

Alcohol consumption within 48 hours of testing can suppress GH secretion. Caloric restriction below approximately 500 kcal/day for more than 5 days can paradoxically either suppress or raise GH depending on the degree and duration of restriction. Standardized pre-test conditions (8-10-hour fast, no alcohol, no vigorous exercise the day before) are specified by the Endocrine Society testing protocol [3].

Pediatric vs. Adult Interpretation: Key Differences

The cutoffs described throughout this article apply to adults. Pediatric GH deficiency uses different stimulation agents (clonidine, levodopa, arginine alone, glucagon) and different peak GH thresholds, historically 10 ng/mL on older assays, now typically 5-7 ng/mL on newer immunoassays depending on laboratory and assay standardization [11]. A child's result should never be interpreted against adult reference ranges.

Transition-age patients (ages 18-25) who had childhood-onset GH deficiency require retesting as adults before continuing rhGH therapy, because a significant minority will have normal GH reserve when retested after completion of linear growth. The Endocrine Society recommends retesting all transition patients except those with a confirmed genetic or structural cause of GH deficiency [3].

Assay Standardization and Why Your Number May Differ Between Labs

GH immunoassay results are not interchangeable across platforms. A peak GH of 4.2 ng/mL on a Roche Elecsys assay is not equivalent to 4.2 ng/mL on a Siemens Immulite assay. Recalibration efforts under the IS 98/574 standard have reduced but not eliminated inter-assay variability [7]. The Growth Hormone Research Society consensus statement published in 2011 explicitly recommends that "diagnostic GH cutpoints need to be assay-specific" [7].

If you were tested at one laboratory and are being followed at a different institution, request documentation of which assay platform and which international standard was used for both tests before interpreting any apparent change in your peak GH response.